Skip to Main Content

The annual Alzheimer’s research meeting known as CTAD was supposed to be a snoozefest this year. That all changed six weeks ago, when Biogen stunned the medical world by bringing an Alzheimer’s drug back from the dead — and vowed to make a detailed scientific case for the decision at the gathering this week.

On Thursday morning, Biogen will give that highly anticipated presentation — livestreamed here — detailing data from two late-stage clinical trials of its drug, known as aducanumab. It will be the highlight of CTAD, short for Clinical Trials on Alzheimer’s Disease.


To recap: Biogen had decided in March to discontinue those studies because the drug appeared to have failed. But in October, the company announced that a new analysis showed that the drug actually reduced decline in patients with early-stage Alzheimer’s in one of its studies and in a subset of the other. What changed? The new analysis included previously unavailable data reflecting a late-stage change Biogen made to its studies: allowing patients to receive higher doses of the medicine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!